Here is a detailed review of the most material insider purchase and sale disclosures made on Monday across U.S. publicly traded companies. The activity spans health-care services, regional banking, financial information providers, energy infrastructure, nuclear technology, mortgage lending, automotive technology and natural gas production. Filings include specific share counts, weighted average prices, transaction dates and notes on trading plans and restricted stock arrangements.
Top buys
-
Option Care Health, Inc. (NASDAQ: OPCH) - Insider buying at the top of the company was conspicuous. Chief Financial Officer Meenal Sethna reported purchasing 16,225 shares on May 4, 2026, for a total consideration of $327,074. The purchases occurred at prices ranging from $19.94 to $20.38 per share, producing a weighted average price of $20.1587 per share. Those transactions took place while the stock traded close to its 52-week low of $18.01 and after a year-to-date decline of 34%.
-
Option Care Health, Inc. (NASDAQ: OPCH) - In a separate filing on the same date, CEO and director John Charles Rademacher disclosed an acquisition of 12,500 shares of common stock on May 4, 2026. The total value of his purchases was $264,706. The acquisition price range was $21.14 to $21.18 per share, with a reported weighted average price of $21.1765 per share. The timing of Mr. Rademacher's purchases is notable against the backdrop of a 24% decline for the stock over the prior week and a 34% drop year-to-date.
-
First Guaranty Bancshares, Inc. (NASDAQ: FGBI) - Director Bruce McAnally purchased 109,051 shares on April 30, 2026, at $9.17 per share, for an aggregate outlay of roughly $999,997. The shares were acquired indirectly by the BMAC Irrevocable Asset Trust, for which Mr. McAnally acts as trustee. The filing states that Mr. McAnally disclaims beneficial ownership other than his pecuniary interest. After the transaction, the trust holds 441,587 shares. The filing notes the stock is trading at about $9.00, up 60% over the last six months, with a market capitalization of $144 million. InvestingPro analysis referenced in the filing indicates FGBI appears overvalued relative to its Fair Value and ranks among stocks on the most overvalued list.
-
S&P Global Inc. (NYSE: SPGI) - Director Robert Edward Moritz Jr. reported buying 1,151.996 shares for a total of $500,000 on April 30, 2026. These purchases were executed at prices between $433.05 and $434.03 per share, resulting in a weighted average price of $434.03 per share. The filing notes SPGI was trading at $424.75, down 18% year-to-date, and that InvestingPro analysis suggests the stock remains undervalued at current levels.
-
S&P Global Inc. (NASDAQ: SPGI) - Catherine R. Clay, CEO of S&P Dow Jones Indices, acquired 2,500 shares of S&P Global common stock on May 1, 2026, at $431.39 per share, for a total purchase price of $1,078,475. Following this transaction, Ms. Clay directly holds 2,500 shares. The filing also disclosed her holdings of Restricted Stock Units (RSUs): two grants totaling 1,325 RSUs and 857 RSUs, both reported on March 1, 2026. Each RSU represents a contingent right to one share of common stock and both grants are scheduled to vest over three years with vesting of 33% on March 1, 2027, 33% on March 1, 2028, and 34% on March 1, 2029.
Top sells
-
Kinetik Holdings Inc. (NASDAQ: KNTK) - Entities associated with I Squared Capital - specifically ISQ Global Fund II GP LLC, I Squared Capital, LLC and ISQ Holdings, LLC - together with Sadek Wahba and Gautam Bhandari, disclosed the sale of Class A Common Stock totaling $27,005,476 on April 30, 2026. The disposition involved 534,564 shares sold at weighted average prices that varied across tranches from $49.2023 to $50.8603 per share. The sale included three blocks: 36,136 shares sold at a weighted average of $49.2023 per share (individual trades between $48.80 and $49.795), 404,268 shares sold at a weighted average of $50.5568 per share (prices from $49.81 to $50.8075), and 94,160 shares sold at a weighted average of $50.8603 per share (prices from $50.81 to $51.07). The shares were trading near a 52-week high of $51.11 after a six-month gain of 37%. InvestingPro analysis cited in the filing indicates the stock remains undervalued relative to a Fair Value of $64.96, and the company is described as offering a 6.6% dividend yield and a roughly $8.26 billion valuation.
-
Oklo Inc. (NASDAQ: OKLO) - Co-Founder and CEO Jacob DeWitte reported selling Class A Common Stock totaling about $14,046,389 on May 1, 2026. The total included 200,000 shares sold at weighted average prices ranging from $69.06 to $70.95 per share. The filing notes that the transactions were carried out under a Rule 10b5-1 trading plan adopted on March 31, 2025. Oklo's stock was trading at $68.60 at the time of the filing, substantially below its 52-week high of $193.84. InvestingPro analysis referenced in the filing states the stock appears overvalued at current levels. The filing breaks out Mr. DeWitte's direct sales to include 16,907 shares at a weighted average price of $69.06 (individual sales between $68.50 and $69.50) and 43,093 shares at a weighted average price of $69.83 (sales between $69.51 and $70.05).
-
UWM Holdings Corp (NASDAQ: UWMC) - President and CEO Mat Ishbia, through SFS Holding Corp - a significant shareholder under his control - reported sales of Class A Common Stock totaling $10,502,841. Executed between April 30 and May 4, 2026, the sales were made at prices ranging from $3.53 to $3.62 per share. The stock is trading at $3.54, close to a 52-week low of $3.38, and the filing notes a 33.5% decline over the past six months for the mortgage lender. The filing also disclosed the conversion of UWM Paired Interests into Class A Common Stock. On April 30, SFS Holding Corp sold 934,061 shares of Class A Common Stock at a weighted average price of $3.53 per share, with individual trades on that date ranging from $3.45 to $3.56. Those dispositions were carried out pursuant to a 10b5-1 trading plan adopted by SFS Corp on September 16, 2025.
-
Tesla, Inc. (NASDAQ: TSLA) - Director Kathleen Wilson-Thompson sold common stock totaling roughly $9.98 million on April 30, 2026. The sales involved 27,389 shares at prices from $369.01 to $384.284 per share. The filing also disclosed the exercise of 40,948 non-qualified stock options, which were acquired at an exercise price of $14.99 per share for a total intrinsic value of $613,810. The options had fully vested by June 18, 2022, and the sale of shares followed that exercise. Tesla shares were reported at $392.51 in the filing, with the stock up 37% over the past year despite a 13% decline year-to-date. InvestingPro analysis cited in the filing indicates the stock appears overvalued on a P/E ratio of 361.
-
ANTERO RESOURCES Corp (NYSE: AR) - CEO and President Michael N. Kennedy reported selling company stock totaling approximately $7.3 million on May 4, 2026. The filing details the sale of 185,826 shares of common stock. Of those, 170,740 shares were sold at prices ranging from $38.57 to $39.56 per share, and an additional 15,086 shares were sold at prices between $39.57 and $39.75 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan that Mr. Kennedy adopted on November 6, 2025. The stock was reported trading at $39.53, up 14.7% year-to-date, with InvestingPro analysis indicating the company appears undervalued based on Fair Value metrics. The filing also noted a P/E ratio of 12.78 and a market capitalization of approximately $12.23 billion.
Context and implications
The filings laid out above provide a granular view of how insiders are deploying capital or monetizing holdings amid recent price moves. Option Care Health's two largest executives buying substantial packages on the same date stands out given the stock's proximity to its 52-week low and its significant year-to-date pullback. Conversely, the sizable dispositions reported at Kinetik, Oklo, UWM, Tesla and Antero Resources reflect a mix of selling through structured trading plans and opportunistic divestitures while prices were elevated or, in some cases, despite recent share price weakness.
Several of the sales were executed under Rule 10b5-1 trading arrangements, which can provide pre-arranged mechanisms for insiders to sell stock without being influenced by near-term market developments. The filings for Oklo, UWM and Antero Resources explicitly identify 10b5-1 plans as the vehicle for the reported dispositions. In other cases, sales followed the exercise of stock options, as reported in the Tesla filing, and indirect trust acquisitions or disclaimers of beneficial ownership are noted in the First Guaranty Bancshares filing.
Key points
- Concentrated insider purchases at Option Care Health by the CFO and the CEO occurred while the stock traded near its 52-week low, signaling direct executive reinvestment in the company.
- Large-scale sales by private equity-affiliated entities at Kinetik and planned dispositions under 10b5-1 at Oklo, UWM and Antero Resources generated multi-million dollar transactions across energy, mortgage lending and nuclear technology sectors.
- S&P Global saw purchases by a director and the CEO of S&P Dow Jones Indices, including disclosures of RSU grants with scheduled multi-year vesting - activity that touches the financial information and index services sector.
Risks and uncertainties
- Insider sales executed under Rule 10b5-1 plans limit the informational content of the transaction timing - this affects interpretation in sectors where large pre-arranged sales occur, such as energy, mortgage lending and technology.
- Market valuations cited in the filings vary by data provider: InvestingPro commentary in the filings labels some stocks as overvalued and others as undervalued, introducing uncertainty for investors trying to infer insider sentiment purely from market metrics.
- Purchases and sales by insiders can be motivated by non-operational considerations - including personal financial planning, tax obligations or diversification - which introduces ambiguity when assessing the transactions' implications for corporate fundamentals across affected sectors.
How to read these signals
Insider buying can be interpreted as a direct statement of confidence by those with the closest view of operations and strategy, especially when purchases come from a company’s most senior executives. Insider selling, however, is not synonymous with a negative view of future prospects; the SEC filings and accompanying notes make clear that insiders often sell for reasons unrelated to company performance, such as estate or tax planning and portfolio diversification. Where disposals are made through pre-established 10b5-1 plans, the timing is often predetermined and may not reflect contemporaneous changes to the insiders' views.
For investors, integrating insider transaction data with other fundamental and technical indicators is essential. The filings provide precise quantities, prices and mechanisms that can be evaluated alongside valuation commentary (as cited from InvestingPro in the filings), recent price performance, and the existence of vesting schedules or trust arrangements. That combined view can help clarify whether insider trades reinforce or diverge from other signals affecting a company’s near-term and long-term outlook.
Final note
The disclosures reviewed here are limited to the details reported in the relevant SEC filings: share counts, transaction dates, prices, total consideration, references to trading plans and notes on vesting or indirect ownership. Where the filings reference analysis from InvestingPro, that commentary is reported as presented. Readers should consider these filings as one input among many when evaluating investment decisions.